Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company’s 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.
Sandgaard also highlighted the submission of a laser-based pulse oximeter to the FDA, aiming for commercialization in 2025. He forecasted 10–15% revenue growth and a doubling of EBITDA in 2025, driven by expansion, employee satisfaction, and a strong focus on innovation.
Proactive: It’s been a very busy 2024 for you and the team at Zynex. What are your overall thoughts on the year?
Thomas Sandgaard: It’s been a huge milestone for us, as we’ve hit $200 million in revenue for the first time in the company’s history while remaining profitable. I can only thank our employees for their hard work in introducing new products and driving increased productivity.
You mentioned new products …